ANABV — AnaptysBio Share News
0.000.00%
Last trade - 00:00- $1.94bn
- $1.91bn
- $234.60m
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged
NASDAQ RESUMED AT 11:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:26 AM
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
U.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
AnaptysBio falls after board approves First Tracks Biotherapeutics spinoff
Brief: Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update
Brief: First Tracks Biotherapeutics, The Planned Spin-Off Of Anaptys, Secures Commitments Of $145 Million In Private Placement
U.S. STOCKS ON THE MOVE-AnaptysBio, Tesla, Intel
AnaptysBio climbs on plans to split into two public companies
AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan
Brief: AnaptysBio Q4 Net Income USD 49.614 Million
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
Brief: Anaptys Files Motion To Dismiss Tesaro'S Claim Of Anticipatory Breach Of Contract In Ongoing Litigation